Susquehanna International Group, LLP Allovir, Inc. Call Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 15, 2024	SELL	$0.72 - $0.82 $163,368 - $186,058	-226,900 Reduced 71.35%	91,100 $65,000
Q1 2024 May 07, 2024	BUY	$0.64 - $0.78 $55,488 - $67,626	86,700 Added 37.48%	318,000 $241,000
Q4 2023 Feb 14, 2024	BUY	$0.68 - $2.39 $149,056 - $523,888	219,200 Added 1811.57%	231,300 $157,000
Q3 2023 Nov 14, 2023	SELL	$2.15 - $3.64 $13,545 - $22,932	-6,300 Reduced 34.24%	12,100 $26,000
Q1 2023 May 16, 2023	BUY	$3.94 - $7.05 $72,496 - $129,720	18,400 New	18,400 $72,000
Q4 2021 Feb 14, 2022	BUY	$12.94 - $25.99 $27,174 - $54,579	2,100 Added 6.14%	36,300 $470,000
Q3 2021 Nov 15, 2021	BUY	$16.97 - $25.06 $580,374 - $857,052	34,200 New	34,200 $857,000

44.6M

14.9K

200

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $53M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.